- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00402363
Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation
1 de diciembre de 2016 actualizado por: GlaxoSmithKline
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation
The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
663
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35215
- GSK Investigational Site
-
Huntsville, Alabama, Estados Unidos, 35801
- GSK Investigational Site
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- GSK Investigational Site
-
-
Arizona
-
Cottonwood, Arizona, Estados Unidos, 86326
- GSK Investigational Site
-
Mesa, Arizona, Estados Unidos, 85206
- GSK Investigational Site
-
Phoenix, Arizona, Estados Unidos, 85006
- GSK Investigational Site
-
Phoenix, Arizona, Estados Unidos, 85032
- GSK Investigational Site
-
Phoenix, Arizona, Estados Unidos, 85014
- GSK Investigational Site
-
Tucson, Arizona, Estados Unidos, 85724
- GSK Investigational Site
-
-
Arkansas
-
Fort Smith, Arkansas, Estados Unidos, 72901
- GSK Investigational Site
-
Hot Springs, Arkansas, Estados Unidos, 71913
- GSK Investigational Site
-
-
California
-
Alamada, California, Estados Unidos, 94501
- GSK Investigational Site
-
Bakersfield, California, Estados Unidos, 93301
- GSK Investigational Site
-
Bakersfield, California, Estados Unidos, 93308
- GSK Investigational Site
-
Beverly Hills, California, Estados Unidos, 90210
- GSK Investigational Site
-
Carmichael, California, Estados Unidos, 95608
- GSK Investigational Site
-
Fair Oaks, California, Estados Unidos, 95628
- GSK Investigational Site
-
Fountain Valley, California, Estados Unidos, 92708
- GSK Investigational Site
-
Loma Linda, California, Estados Unidos, 92354
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90073
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90048
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90033
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90211
- GSK Investigational Site
-
Merced, California, Estados Unidos, 95348
- GSK Investigational Site
-
Palm Springs, California, Estados Unidos, 92262
- GSK Investigational Site
-
Poway, California, Estados Unidos, 92064
- GSK Investigational Site
-
Redondo Beach, California, Estados Unidos, 90277
- GSK Investigational Site
-
Sacramento, California, Estados Unidos, 95819
- GSK Investigational Site
-
San Diego, California, Estados Unidos, 92123
- GSK Investigational Site
-
San Diego, California, Estados Unidos, 92120
- GSK Investigational Site
-
San Diego, California, Estados Unidos, 92161
- GSK Investigational Site
-
Vista, California, Estados Unidos, 92081
- GSK Investigational Site
-
Walnut Creek, California, Estados Unidos, 94598
- GSK Investigational Site
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- GSK Investigational Site
-
Colorado Springs, Colorado, Estados Unidos, 80907
- GSK Investigational Site
-
Littleton, Colorado, Estados Unidos, 80120
- GSK Investigational Site
-
-
Connecticut
-
Bridgeport, Connecticut, Estados Unidos, 06606
- GSK Investigational Site
-
Farmington, Connecticut, Estados Unidos, 06030
- GSK Investigational Site
-
Guilford, Connecticut, Estados Unidos, 06437
- GSK Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 20010
- GSK Investigational Site
-
Washington, District of Columbia, Estados Unidos, 20017
- GSK Investigational Site
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- GSK Investigational Site
-
Bay Pines, Florida, Estados Unidos, 33744
- GSK Investigational Site
-
Daytona Beach, Florida, Estados Unidos, 32114
- GSK Investigational Site
-
Delray Beach, Florida, Estados Unidos, 33484
- GSK Investigational Site
-
Fort Meyers, Florida, Estados Unidos, 33919
- GSK Investigational Site
-
Gainesville, Florida, Estados Unidos, 32605
- GSK Investigational Site
-
Hudson, Florida, Estados Unidos, 34667
- GSK Investigational Site
-
Jacksonville, Florida, Estados Unidos, 32216
- GSK Investigational Site
-
Jacksonville, Florida, Estados Unidos, 32207
- GSK Investigational Site
-
Jupiter, Florida, Estados Unidos, 33458
- GSK Investigational Site
-
Kissimmee, Florida, Estados Unidos, 34741
- GSK Investigational Site
-
Largo, Florida, Estados Unidos, 33773
- GSK Investigational Site
-
Melbourne, Florida, Estados Unidos, 32901
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33136
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33137
- GSK Investigational Site
-
Miami, Florida, Estados Unidos, 33176
- GSK Investigational Site
-
Ocala, Florida, Estados Unidos, 34471
- GSK Investigational Site
-
Orlando, Florida, Estados Unidos, 32803
- GSK Investigational Site
-
Ormond Beach, Florida, Estados Unidos, 32174
- GSK Investigational Site
-
Pensacola, Florida, Estados Unidos, 32514
- GSK Investigational Site
-
Pinellas Park, Florida, Estados Unidos, 33781
- GSK Investigational Site
-
Tampa, Florida, Estados Unidos, 33607
- GSK Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30342
- GSK Investigational Site
-
Atlanta, Georgia, Estados Unidos, 30322
- GSK Investigational Site
-
Atlanta, Georgia, Estados Unidos, 30328
- GSK Investigational Site
-
Decatur, Georgia, Estados Unidos, 30030
- GSK Investigational Site
-
Tucker, Georgia, Estados Unidos, 30084
- GSK Investigational Site
-
-
Illinois
-
Bannockburn, Illinois, Estados Unidos, 60015
- GSK Investigational Site
-
Gurnee, Illinois, Estados Unidos, 60031
- GSK Investigational Site
-
Normal, Illinois, Estados Unidos, 61761
- GSK Investigational Site
-
Peoria, Illinois, Estados Unidos, 61603
- GSK Investigational Site
-
-
Indiana
-
Elkhart, Indiana, Estados Unidos, 46514
- GSK Investigational Site
-
Indianapolis, Indiana, Estados Unidos, 46260
- GSK Investigational Site
-
La Porte, Indiana, Estados Unidos, 46350
- GSK Investigational Site
-
South Bend, Indiana, Estados Unidos, 46601
- GSK Investigational Site
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66102
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40205
- GSK Investigational Site
-
Mount Sterling, Kentucky, Estados Unidos, 40353
- GSK Investigational Site
-
-
Louisiana
-
Covington, Louisiana, Estados Unidos, 70433
- GSK Investigational Site
-
Lacombe, Louisiana, Estados Unidos, 70445
- GSK Investigational Site
-
-
Maine
-
Auburn, Maine, Estados Unidos, 04210
- GSK Investigational Site
-
Biddeford, Maine, Estados Unidos, 04005
- GSK Investigational Site
-
Portland, Maine, Estados Unidos, 04106
- GSK Investigational Site
-
Scarborough, Maine, Estados Unidos, 04074
- GSK Investigational Site
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos, 20401
- GSK Investigational Site
-
-
Massachusetts
-
Ayer, Massachusetts, Estados Unidos, 01432
- GSK Investigational Site
-
Brookline, Massachusetts, Estados Unidos, 02446
- GSK Investigational Site
-
Worcester, Massachusetts, Estados Unidos, 01655
- GSK Investigational Site
-
-
Michigan
-
Alpena, Michigan, Estados Unidos, 49707
- GSK Investigational Site
-
Cadillac, Michigan, Estados Unidos, 49601
- GSK Investigational Site
-
Detroit, Michigan, Estados Unidos, 48201
- GSK Investigational Site
-
Kalamazoo, Michigan, Estados Unidos, 49048
- GSK Investigational Site
-
Lansing, Michigan, Estados Unidos, 48910
- GSK Investigational Site
-
-
Minnesota
-
Mineappolis, Minnesota, Estados Unidos, 55417
- GSK Investigational Site
-
Rochester Hills, Minnesota, Estados Unidos, 48307
- GSK Investigational Site
-
St Paul, Minnesota, Estados Unidos, 55102
- GSK Investigational Site
-
-
Mississippi
-
Gulfport, Mississippi, Estados Unidos, 39503
- GSK Investigational Site
-
-
Montana
-
Billings, Montana, Estados Unidos, 59101
- GSK Investigational Site
-
Kalispell, Montana, Estados Unidos, 59901
- GSK Investigational Site
-
Missoula, Montana, Estados Unidos, 59802
- GSK Investigational Site
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07962
- GSK Investigational Site
-
Summit, New Jersey, Estados Unidos, 07901
- GSK Investigational Site
-
Wayne, New Jersey, Estados Unidos, 07470
- GSK Investigational Site
-
-
New York
-
Babylon, New York, Estados Unidos, 11702
- GSK Investigational Site
-
Buffalo, New York, Estados Unidos, 14215
- GSK Investigational Site
-
Buffalo, New York, Estados Unidos, 14209
- GSK Investigational Site
-
Mineola, New York, Estados Unidos, 11501
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10032
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10025
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10021
- GSK Investigational Site
-
New York, New York, Estados Unidos, 10029
- GSK Investigational Site
-
Troy, New York, Estados Unidos, 12180
- GSK Investigational Site
-
West Islip, New York, Estados Unidos, 11794
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- GSK Investigational Site
-
Charlotte, North Carolina, Estados Unidos, 28080
- GSK Investigational Site
-
Hickory, North Carolina, Estados Unidos, 28601
- GSK Investigational Site
-
Statesville, North Carolina, Estados Unidos, 28625
- GSK Investigational Site
-
-
North Dakota
-
Grand Forks, North Dakota, Estados Unidos, 58201
- GSK Investigational Site
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44304
- GSK Investigational Site
-
Bryan, Ohio, Estados Unidos, 43506
- GSK Investigational Site
-
Cincinnati, Ohio, Estados Unidos, 45219
- GSK Investigational Site
-
Cleveland, Ohio, Estados Unidos, 44106
- GSK Investigational Site
-
Fairview Park, Ohio, Estados Unidos, 44126
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73103
- GSK Investigational Site
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- GSK Investigational Site
-
Oklahoma City, Oklahoma, Estados Unidos, 73109
- GSK Investigational Site
-
-
Oregon
-
Corvalis, Oregon, Estados Unidos, 97330
- GSK Investigational Site
-
Hillsboro, Oregon, Estados Unidos, 97123-4117
- GSK Investigational Site
-
Portland, Oregon, Estados Unidos, 97220
- GSK Investigational Site
-
Portland, Oregon, Estados Unidos, 97223
- GSK Investigational Site
-
-
Pennsylvania
-
Beaver, Pennsylvania, Estados Unidos, 15009
- GSK Investigational Site
-
Greensburg, Pennsylvania, Estados Unidos, 15601
- GSK Investigational Site
-
Hershey, Pennsylvania, Estados Unidos, 17033
- GSK Investigational Site
-
Langhorne, Pennsylvania, Estados Unidos, 19047
- GSK Investigational Site
-
Philadelphia, Pennsylvania, Estados Unidos, 19102
- GSK Investigational Site
-
Ridley Park, Pennsylvania, Estados Unidos, 19078
- GSK Investigational Site
-
West Chester, Pennsylvania, Estados Unidos, 19380
- GSK Investigational Site
-
Wynnewood, Pennsylvania, Estados Unidos, 19096
- GSK Investigational Site
-
Wyomissing, Pennsylvania, Estados Unidos, 19610
- GSK Investigational Site
-
-
Rhode Island
-
Cranston, Rhode Island, Estados Unidos, 02920
- GSK Investigational Site
-
Pawtucket, Rhode Island, Estados Unidos, 02860
- GSK Investigational Site
-
Westerly, Rhode Island, Estados Unidos, 02891
- GSK Investigational Site
-
-
South Carolina
-
Greer, South Carolina, Estados Unidos, 29651
- GSK Investigational Site
-
Spartanburg, South Carolina, Estados Unidos, 29302
- GSK Investigational Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- GSK Investigational Site
-
-
Tennessee
-
Jackson, Tennessee, Estados Unidos, 38301
- GSK Investigational Site
-
Memphis, Tennessee, Estados Unidos, 38120
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- GSK Investigational Site
-
Beaumont, Texas, Estados Unidos, 77702
- GSK Investigational Site
-
Corpus Christi, Texas, Estados Unidos, 78404
- GSK Investigational Site
-
Dallas, Texas, Estados Unidos, 75230
- GSK Investigational Site
-
Dallas, Texas, Estados Unidos, 75231
- GSK Investigational Site
-
Houston, Texas, Estados Unidos, 77074
- GSK Investigational Site
-
Houston, Texas, Estados Unidos, 77090
- GSK Investigational Site
-
Humble, Texas, Estados Unidos, 77338
- GSK Investigational Site
-
Lubbock, Texas, Estados Unidos, 79410
- GSK Investigational Site
-
McKinney, Texas, Estados Unidos, 75069
- GSK Investigational Site
-
Odessa, Texas, Estados Unidos, 79761
- GSK Investigational Site
-
Odessa, Texas, Estados Unidos, 79764
- GSK Investigational Site
-
Orange, Texas, Estados Unidos, 77630
- GSK Investigational Site
-
Tyler, Texas, Estados Unidos, 75701
- GSK Investigational Site
-
Waco, Texas, Estados Unidos, 76712
- GSK Investigational Site
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84124
- GSK Investigational Site
-
-
Virginia
-
Arlington, Virginia, Estados Unidos, 22204
- GSK Investigational Site
-
Chesapeake, Virginia, Estados Unidos, 23510
- GSK Investigational Site
-
Galax, Virginia, Estados Unidos, 24333
- GSK Investigational Site
-
Richlands, Virginia, Estados Unidos, 24641
- GSK Investigational Site
-
Richmond, Virginia, Estados Unidos, 23249
- GSK Investigational Site
-
Richmond, Virginia, Estados Unidos, 23294
- GSK Investigational Site
-
Springfield, Virginia, Estados Unidos, 22151
- GSK Investigational Site
-
-
Washington
-
Burien, Washington, Estados Unidos, 98166
- GSK Investigational Site
-
-
West Virginia
-
Huntington, West Virginia, Estados Unidos, 25701
- GSK Investigational Site
-
-
Wisconsin
-
Beloit, Wisconsin, Estados Unidos, 53511
- GSK Investigational Site
-
Madison, Wisconsin, Estados Unidos, 53792
- GSK Investigational Site
-
Marshfield, Wisconsin, Estados Unidos, 54449
- GSK Investigational Site
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- GSK Investigational Site
-
Wausau, Wisconsin, Estados Unidos, 54401
- GSK Investigational Site
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Men and women age 18 years or older
- History of symptomatic atrial fibrillation (either paroxysmal or persistent)
- Provide written informed consent and authorization for protected health information disclosure
Exclusion Criteria:
- Permanent (chronic) atrial fibrillation
- Antiarrhythmic drug therapy which cannot be stopped
- Use of amiodarone with prior 6 months
- History of unsuccessful cardioversion
- History of certain cardiovascular conditions or cardiac surgery within prior 6 months
- History of stroke within prior 6 months
- Implanted cardio-defibrillator
- Certain circulatory, thyroid, pulmonary, liver, kidney, musculoskeletal or metabolic conditions, or cancer (except non-melanoma skin cancer)
- Poorly controlled diabetes
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
|
|
|
Experimental: omega-3-acid ethyl esters
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter
Periodo de tiempo: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF /Flutter was defined as AF/Flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Persistent AF and in Both AF Subgroups Combined With an Event of Documented Symptomatic AF/Flutter
Periodo de tiempo: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal AF or Persistent AF With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter)
Periodo de tiempo: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter)
Periodo de tiempo: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF/Flutter
Periodo de tiempo: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF/Flutter
Periodo de tiempo: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter)
Periodo de tiempo: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter)
Periodo de tiempo: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.
|
From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter
Periodo de tiempo: From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants in the Combined AF Subgroups With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter
Periodo de tiempo: From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF.
Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals.
"Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24)
|
|
Number of Participants With Paroxysmal or Persistent AF With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter)
Periodo de tiempo: From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
|
Number of Participants in the Combined AF Subgroups With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter)
Periodo de tiempo: From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.
|
From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24)
|
|
Annualized Number of AF/Flutter Rescue Episodes During the Treatment Period
Periodo de tiempo: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Rescue was defined as any pharmacological/electrical/surgical intervention for the termination/prevention of AF/flutter with a maximum of one rescue episode counted per day.
Note: all annualized values were calculated by counting the number of rescue episodes, dividing by the number of days on treatment, then multiplying that number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
|
Annualized Cumulative Frequency of Symptomatic AF/Flutter Recurrences During the Treatment Period
Periodo de tiempo: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Values were annualized by counting the number of episodes of symptomatic AF/flutter recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
|
Annualized Cumulative Frequency of Symptomatic AF Recurrences During the Treatment Period
Periodo de tiempo: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Values were annualized by counting the number of episodes of symptomatic AF recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.
|
From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24)
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010 Dec 1;304(21):2363-72. doi: 10.1001/jama.2010.1735. Epub 2010 Nov 15.
- Pratt CM, Reiffel JA, Ellenbogen KA, Naccarelli GV, Kowey PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J. 2009 Aug;158(2):163-169.e1-3. doi: 10.1016/j.ahj.2009.05.024.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de noviembre de 2006
Finalización primaria (Actual)
1 de enero de 2010
Finalización del estudio (Actual)
1 de enero de 2010
Fechas de registro del estudio
Enviado por primera vez
20 de noviembre de 2006
Primero enviado que cumplió con los criterios de control de calidad
20 de noviembre de 2006
Publicado por primera vez (Estimar)
22 de noviembre de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
30 de enero de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
1 de diciembre de 2016
Última verificación
1 de diciembre de 2016
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- OM8 Afib
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Sí
Descripción del plan IPD
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Datos del estudio/Documentos
-
Formulario de consentimiento informado
Identificador de información: OM8 AfibComentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de datos de participantes individuales
Identificador de información: OM8 AfibComentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulario de informe de caso anotado
Identificador de información: OM8 AfibComentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Especificación del conjunto de datos
Identificador de información: OM8 AfibComentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudio
Identificador de información: OM8 AfibComentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan de Análisis Estadístico
Identificador de información: OM8 AfibComentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Informe de estudio clínico
Identificador de información: OM8 AfibComentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .